 Clover Biopharmaceuticals and Dynavax Technologies Corporation NASDAQ: DVAX have executed the commercial supply agreement of Dynavaxs CpG 1018TM advanced adjuvant for use in Clovers protein-based COVID-19 vaccine candidate, SCB-2019 CpG 1018Alum. The commercial supply agreement extends to the end of 2022. 